Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
Saved in:
| Title: | Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities. |
|---|---|
| Authors: | File TM Jr; Summa Health, Akron, OH, USA., Alexander E; Nabriva Therapeutics US, Inc., Fort Washington, PA, USA. elizabethlaurenalexander15@gmail.com.; Vir Biotechnology, Inc., 499 Illinois Street, Suite 500, San Francisco, CA, 94158, USA. elizabethlaurenalexander15@gmail.com., Goldberg L; Nabriva Therapeutics US, Inc., Fort Washington, PA, USA., Das AF; Das Consulting, Guerneville, CA, USA., Sandrock C; UC Davis School of Medicine, Sacramento, CA, USA., Paukner S; Nabriva Therapeutics GmbH, Vienna, Austria., Moran GJ; Olive View-UCLA Medical Center, Los Angeles, CA, USA. |
| Source: | BMC pulmonary medicine [BMC Pulm Med] 2021 May 08; Vol. 21 (1), pp. 154. Date of Electronic Publication: 2021 May 08. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2466 (Electronic) Linking ISSN: 14712466 NLM ISO Abbreviation: BMC Pulm Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1471-2466 |
|---|---|
| DOI: | 10.1186/s12890-021-01472-z |
